Mitochondrial DNA Sample Clauses

Mitochondrial DNA. Sixteen unique mitochondrial haplotypes were identified from the 182 raccoons sampled in northeastern Ohio (Table 2.4). Table 2.4 Definition of 16 unique mitochondrial haplotypes found in 182 raccoons in northeastern Ohio. Polymorphic sites contributing to haplotype definitions are shown with individual site numbers listed vertically. 000122222222222222222222222222222222222222233333333333444 669305666666677777777778888888888999999999903334778999355 127502345678901234567890123456789012345678997892120128727 OH1 AGTCCAAACACCTACATATCAAATACCCACTGCACCACCCCATT-AGGATCGGCAGA OH2 G OH3 ................................................G G OH4 ...A.............................................C...T..G OH5 ...........................................C G OH6 GAC..G..........................................X.X.XX..G OH7 GA...G. G.T.ATG.G OH8 GA...G.................C......................AA..TAAT..G OH9gap GA...G- ....G X.XX..G OH10 GA...G. G.T..T..G OH11 GA..TG. X.XX.XX OH12 GA...G..........................................X.X.XX..G OH13 GA...G............................................X.XX..G OH13gap GA...G- OH14gap GA...G- OH15gap GA...G- .........X.XX..G ...T...X.X.XX..G A.T...X.X.XX..G No double peaks which might be indicative of nuclear copies of mitochondrial DNA (numts) were observed. Of 460 aligned sites, 57 sites were variable. A single nucleotide insertion was found in 2 haplotypes. In addition, 3 haplotypes possessed a 35 bp deletion and another haplotype contained a 36 bp deletion. For the purpose of nucleotide diversity calculations and subsequent analyses, the 35 bp gap was treated as a single evolutionary event. The most common haplotype in the region, OH12, was identified as the probable ancestral haplotype (Figure 2.4). OH13gap most likely gave rise to the other haplotypes containing insertion/deletion events. Spatial structuring within the area was observed for some of the less frequently sampled mitochondrial haplotypes whereas a large amount of overlap was observed in the distributions of those that were encountered more frequently. Haplotype diversity was moderately high (0.8238 ± 0.0159) whereas nucleotide diversity was relatively low (0.0091 ± 0.0051) suggesting that most of the haplotypes in the region differed only by a few nucleotides (Figure 2.4). If multiple populations had been present, one might have expected to observe spatially segregated, distinct haplotype lineages with varying haplotype frequencies, and perhaps potential differences in RRV...
AutoNDA by SimpleDocs
Mitochondrial DNA. Ninety-two distinct mitochondrial haplotypes were identified (Figure 3.5). No double peaks, which might be indicative of nuclear copies of DNA (numts), were observed. Of 440 aligned nucleotides, 71 sites were polymorphic. Haplotype diversity was relatively high (0.8692 ± 0.0304) whereas nucleotide diversity was low (0.0139 ± 0.0073; Table 3.4). The majority of haplotypes differed by a small number of substitutions, although a 35 bp deletion was present in 4 separate haplotypes found in the northeastern part of the study area. Furthermore, one haplotype not containing the deletion event contained an additional 36 bp insertion. For all population genetic analyses, these insertion/deletion events were represented as single evolutionary events. Three main haplotype groups were identified (Figure 3.5), roughly corresponding to the populations described based on the microsatellite results: one consisting of samples from all localities except Florida (I); another group restricted to Ohio, Tennessee, Kentucky, and West Virginia (II); and a final group containing samples from Florida, Georgia, Alabama, and Tennessee (III). All 3 haplotype groups were represented in Tennessee. Most haplotypes were limited in range, although a single nearly cosmopolitan haplotype belonging to haplotype group I was found in every location sampled with the exception of Florida. This particular haplotype was widely distributed and occurred at the highest overall frequency (Figure 3.5), resulting in its identification as the likely ancestral haplotype. OH, WV, VA, KY, TN, NC, SC, GA, AL OH, KY, TN, WV FL, GA, AL, TN Figure 3.5 Distribution of the 3 haplotype groups—states with a single haplotype group are shown with vertical lines; states where 2 haplotype groups occur are shown with dots; all 3 haplotype groups are found in Tennessee, shown in purple. Node size corresponds to relative haplotype frequency. Unsampled haplotypes are shown as small, open circles. Branch lengths correspond to the number of mutational steps between haplotypes. The 4 haplotypes in group I containing a 35 bp deletion event are indicated via a light gray line with a break. Table 3.4 Haplotype and nucleotide diversity indices and neutrality tests. Sample size (n), haplotype diversity (Ĥ), and nucleotide diversity (π). For Chakraborty’s test, the number indicates number of observed alleles (for this test, p < 0.02 is equivalent to p < 0.05). Population 1 2 3 Avg N 218 228 179 208 Ĥ 0.8437±0.0146 0.9633±0.0077 0.80...
Mitochondrial DNA. An approximately 450 base pair (bp) portion of the mitochondrial control region (D loop) was amplified from the previously isolated genomic DNA using primers H16498 (5’-CCTGAACTAGGAACCAGATG-3’) and L15774 (5’- GTAAAACGACGGCCAGTACATGAATTGGAGGACAACCAGT-3’) of Xxxxxxx and Xxxxxx (1991). Polymerase chain reaction (PCR) amplifications were performed in 50 μl volumes containing 500 ng of DNA, 5 μl of 10X Buffer, 4 μl of MgCl2, 2 μl of 10 mM dNTPs, 2.5 μl of each 20 μM primer, and 1.5 U Taq polymerase. Thermal profile conditions consisted of 1 cycle of initial denaturation at 95°C for 10 minutes; 30 cycles of 94°C denaturation for 1 minute, 55°C annealing for 1 minute, and 72°C extension for 1 minute; and a final extension of 72°C for 30 minutes. PCR products were purified with Performa® spin columns (Edge Biosystems, Gaithersburg, Maryland). After cycle- sequencing and additional purification, samples were run on an ABI PRISM® 3100 Genetic Analyzer using BigDye chain terminators (Applied Biosystems, Foster City, California). Sequencher 3.0 software (Gene Codes, Ann Arbor, Michigan) was used to align fragments and to proof nucleotide sequences, and CLUSTAL X (Xxxxxxxx et al. 1997) was used for multiple sequence alignments. Unique haplotypes were determined using Collapse 1.2 (available from xxxx://xxxxxx.xxxxx.xx), and a minimum spanning network of haplotypes was constructed using TCS 1.21 (Xxxxxxx et al. 2000). Haplotype diversity and nucleotide diversity indices were calculated from the data using Arlequin 3.11 software (Excoffier et al. 2005). To test for isolation by distance, a Mantel test was performed with 1,000 permutations using the genetic and geographic distances calculated between all samples in Microsoft Excel with PopTools version 2.7 (Hood 2006).
Mitochondrial DNA. Xxxxxxxx xxxx was generated for an approximately 450 base pair (bp) portion of the mitochondrial control region (D loop) from genomic DNA using the primers H16498 and L15774 (Xxxxxxx and Xxxxxx 1991; see also Chapter 2). Polymerase chain reaction (PCR) amplifications were performed in 50 μl volumes with 500 ng of DNA, 5 μl of 10X Buffer, 4 μl of MgCl2, 2 μl of 10 mM dNTPs, 2.5 μl of each 20 μM primer, and 1.5 U Taq polymerase. Thermal profile conditions consisted of 1 cycle of initial denaturation at 95°C for 10 minutes; 30 cycles of 94°C denaturation for 1 minute, 55°C annealing for 1 minute, and 72°C extension for 1 minute; and a final extension of 72°C for 30 minutes. After cycle-sequencing reactions and additional purification, samples were run on an ABI PRISM® 3100 Genetic Analyzer using BigDye chain terminators (Applied Biosystems, Foster City, California). For analyses based on mitochondrial DNA sequencing, nucleotide fragments were aligned and proofed with Sequencher 3.0 software (Gene Codes, Ann Arbor, Michigan), and a multiple sequence alignment was generated using CLUSTAL X (Xxxxxxxx et al.

Related to Mitochondrial DNA

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Rhytidectomy Scar revision, regardless of symptoms. • Sclerotherapy for spider veins. • Skin tag removal. • Subcutaneous injection of filling material. • Suction assisted Lipectomy. • Tattooing or tattoo removal except tattooing of the nipple/areola related to a mastectomy. • Treatment of vitiligo. • Standby services of an assistant surgeon or anesthesiologist. • Orthodontic services related to orthognathic surgery. • Cosmetic procedures when performed primarily: o to refine or reshape body structures or dental structures that are not functionally impaired; o to improve appearance or self-esteem; or o for other psychological, psychiatric or emotional reasons. • Drugs, biological products, hospital charges, pathology, radiology fees and charges for surgeons, assistant surgeons, attending physicians and any other incidental services, which are related to cosmetic surgery.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Infection Control Consistent with the Centers for Disease Control and Prevention Guideline for Infection Control in Health Care Personnel, and University Policy 3364-109-EH-603, the parties agree that all bargaining unit employees who come in contact with patients in the hospital or ambulatory care clinics will need to be vaccinated against influenza when flu season begins each fall. The influenza vaccine will be offered to all health care workers, including pregnant women, before the influenza season, unless otherwise medically contraindicated or it compromises sincerely held religious beliefs.

  • Prosthodontics We Cover prosthodontic services as follows: • Removable complete or partial dentures, for Members 15 years of age and above, including six (6) months follow-up care; • Additional services including insertion of identification slips, repairs, relines and rebases and treatment of cleft palate; and • Interim prosthesis for Members five (5) to 15 years of age. We do not Cover implants or implant related services. Fixed bridges are not Covered unless they are required: • For replacement of a single upper anterior (central/lateral incisor or cuspid) in a patient with an otherwise full complement of natural, functional and/or restored teeth; • For cleft palate stabilization; or • Due to the presence of any neurologic or physiologic condition that would preclude the placement of a removable prosthesis, as demonstrated by medical documentation.

  • Dienste Und Materialien Von Drittanbietern (a) Die Apple-Software gewährt möglicherweise Zugang zu(m) iTunes Store, App Store, Apple Books, Game Center, iCloud, Karten von Apple und zu anderen Diensten und Websites von Apple und Drittanbietern (gemeinsam und einzeln als „Dienste“ bezeichnet). Solche Dienste sind möglicherweise nicht in xxxxx Sprachen oder in xxxxx Ländern verfügbar. Die Nutzung dieser Dienste erfordert Internetzugriff und die Nutzung bestimmter Dienste erfordert möglicherweise eine Apple-ID, setzt möglicherweise dein Einverständnis mit zusätzlichen Servicebedingungen voraus und unterliegt unter Umständen zusätzlichen Gebühren. Indem du diese Software zusammen mit einer Apple-ID oder einem anderen Apple-Dienst verwendest, erklärst du dein Einverständnis mit den anwendbaren Servicebedingungen für diesen Dienst, z. B. den neuesten Apple Media Services-Bedingungen für das Land, in dem du auf diese Services zugreifst, die du über die Webseite xxxxx://xxx.xxxxx.xxx/legal/ internet-services/itunes/ anzeigen und nachlesen kannst

Time is Money Join Law Insider Premium to draft better contracts faster.